{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:36:27Z","timestamp":1792712187096,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T00:00:00Z","timestamp":1685232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T00:00:00Z","timestamp":1685232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008130","name":"Helsinn Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12325-023-02537-7","type":"journal-article","created":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T08:02:01Z","timestamp":1685260921000},"page":"3217-3226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy"],"prefix":"10.1007","volume":"40","author":[{"given":"Rudolph M.","family":"Navari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie W.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Shoaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risho","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,28]]},"reference":[{"key":"2537_CR1","unstructured":"The National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: Antiemesis, version 1. 2021. 2021."},{"issue":"14 Suppl","key":"2537_CR2","first-page":"S259","volume":"23","author":"N Adel","year":"2017","unstructured":"Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017;23(14 Suppl):S259\u201365.","journal-title":"Am J Manag Care"},{"key":"2537_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021;26: 100278.","journal-title":"Cancer Treat Res Commun"},{"key":"2537_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol. 2016;99:13\u201336.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2537_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","volume":"19","author":"TA Burke","year":"2011","unstructured":"Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19(1):131\u201340.","journal-title":"Support Care Cancer"},{"issue":"6","key":"2537_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","volume":"19","author":"A Haiderali","year":"2011","unstructured":"Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer. 2011;19(6):843\u201351.","journal-title":"Support Care Cancer"},{"issue":"14","key":"2537_CR7","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374(14):1356\u201367.","journal-title":"N Engl J Med"},{"key":"2537_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","volume":"722","author":"K Jordan","year":"2014","unstructured":"Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197\u2013202.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"2537_CR9","doi-asserted-by":"publisher","DOI":"10.2196\/27024","volume":"9","author":"ASM Mosa","year":"2021","unstructured":"Mosa ASM, Rana MKZ, Islam H, Hossain A, Yoo I. A smartphone-based decision support tool for predicting patients at risk of chemotherapy-induced nausea and vomiting: retrospective study on app development using decision tree induction. JMIR Mhealth Uhealth. 2021;9(12):e27024.","journal-title":"JMIR Mhealth Uhealth"},{"issue":"7","key":"2537_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015645","volume":"7","author":"U Restelli","year":"2017","unstructured":"Restelli U, Saibene G, Nardulli P, et al. Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open. 2017;7(7):e015645.","journal-title":"BMJ Open"},{"issue":"8","key":"2537_CR11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1080\/13696998.2019.1620244","volume":"22","author":"SH Park","year":"2019","unstructured":"Park SH, Binder G, Corman S, Botteman M. Budget impact of netupitant\/palonosetron for the prevention of chemotherapy-induced nausea and vomiting. J Med Econ. 2019;22(8):840\u20137.","journal-title":"J Med Econ"},{"issue":"2","key":"2537_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00520-019-04824-y","volume":"28","author":"M Botteman","year":"2020","unstructured":"Botteman M, Nickel K, Corman S, Turini M, Binder G. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support Care Cancer. 2020;28(2):857\u201366.","journal-title":"Support Care Cancer"},{"key":"2537_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07339-1","author":"J Nilsson","year":"2022","unstructured":"Nilsson J, Piovesana V, Turini M, Lezzi C, Eriksson J, Aapro M. Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective. Support Care Cancer. 2022. https:\/\/doi.org\/10.1007\/s00520-022-07339-1.","journal-title":"Support Care Cancer"},{"issue":"1","key":"2537_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40487-022-00188-2","volume":"10","author":"A Hata","year":"2022","unstructured":"Hata A, Shiraishi Y, Inui N, et al. Exploratory analysis comparing fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase 3 study (CONSOLE). Oncol Ther. 2022;10(1):253\u201362.","journal-title":"Oncol Ther"},{"key":"2537_CR15","unstructured":"Agency for Healthcare Research and Quality. All-payer claims databases. 2022. https:\/\/www.ahrq.gov\/data\/apcd\/index.html. Accessed 24 Apr 2023."},{"key":"2537_CR16","unstructured":"U.S Bureau of Labor Statistics Consumer Price Index. 2022. https:\/\/www.bls.gov\/cpi\/. Accessed 24 Apr 2023."},{"issue":"2","key":"2537_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"L Zhang","year":"2018","unstructured":"Zhang L, Lu S, Feng J, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018;29(2):452\u20138.","journal-title":"Ann Oncol"},{"issue":"7","key":"2537_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25(7):1333\u20139.","journal-title":"Ann Oncol"},{"issue":"7","key":"2537_CR19","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340\u20136.","journal-title":"Ann Oncol"},{"issue":"23","key":"2537_CR20","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.2217\/fon-2021-0023","volume":"17","author":"RM Navari","year":"2021","unstructured":"Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari S, Roeland EJ. Single-dose netupitant\/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021;17(23):3027\u201335.","journal-title":"Future Oncol"},{"issue":"2","key":"2537_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","volume":"40","author":"A Hata","year":"2022","unstructured":"Hata A, Okamoto I, Inui N, et al. Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol. 2022;40(2):180\u20138.","journal-title":"J Clin Oncol"},{"key":"2537_CR22","unstructured":"Merck & Co. I. EMEND\u00ae for Injection [package insert]: U.S. Food and Drug Administration website. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022023s017lbl.pdf. Accessed 24 Apr 2023."},{"key":"2537_CR23","unstructured":"Pharmaceuticals HB. AKYNZEO\u00ae [package insert]: U.S. Food and Drug Administration website. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210493s000lbl.pdf. Accessed 24 Apr 2023."},{"key":"2537_CR24","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0972","author":"WW Nelson","year":"2023","unstructured":"Nelson WW, Vaidya V, Scott JA, et al. Antiemetic use and chemotherapy induced nausea and vomiting\u00a0related hospitalization costs after highly or moderately emetogenic chemotherapy. Future Oncol. 2023. https:\/\/doi.org\/10.2217\/fon-2022-0972.","journal-title":"Future Oncol"},{"key":"2537_CR25","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212298","volume":"6","author":"H Cawston","year":"2017","unstructured":"Cawston H, Bourhis F, Eriksson J, et al. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context. 2017;6:212298.","journal-title":"Drugs Context"},{"issue":"5","key":"2537_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/14737167.2019.1650644","volume":"19","author":"J Giuliani","year":"2019","unstructured":"Giuliani J, Bonetti A. Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment. Expert Rev Pharmacoecon Outcomes Res. 2019;19(5):505\u20138.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"2537_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/CCO.0000000000000634","volume":"32","author":"J Giuliani","year":"2020","unstructured":"Giuliani J, Bonetti A. Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data. Curr Opin Oncol. 2020;32(4):269\u201373.","journal-title":"Curr Opin Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02537-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02537-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02537-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:18:13Z","timestamp":1686806293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02537-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,28]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2537"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02537-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,28]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}